Onco Actu du 23 mai 2016

	2.6 Etiologie - Environnement
Europe stalls weed killer renewal, again [Science] The commission yesterday said it would “reflect on the outcome of the discussions.” The source close to the talks says the commission may try to sway influential member states, such as Germany, to weigh in favor of the renewal while it schedules another vote.
	3.1 Tabac
How big tobacco lost its final fight for hearts, lungs and minds [The Guardian] The tobacco giants’ failure to win their case has left them picking up a multimillion pound legal bill and scrambling to calculate the devastating impact it will have on the value of their brands.
	3.6 Prévention - Activité physique
Healthier lifestyles 'could cut cancer death rates' [NHS Choices] This study has limitations, including the population group, which only involved white American health professionals, and the possibility that the estimates are inaccurate.
Can exercise really reduce the risk of getting cancer? [The Guardian] While it hasn’t been proved that physical activity mitigates your likelihood of getting the disease, the evidence shows a strong link – so get moving.
	4.12 Biopsies liquides
A Liquid Biopsy–based Test to Detect BRAF V600 Mutations in Advanced Cancers is Comparable to Standard Invasive Tests [AACR] Test has 90-minute turnaround time and can predict therapy response over the course of treatment.
	4.8 Dép., diag. & prono. - Droit
Myriad Genetics embroiled in breast-cancer data fight — again [Nature News & Comment] Complaint to US government alleges that diagnostics company violated individuals' right to access health information.
	5. Traitements
Glowing tumors light a path to cancer treatment [MIT News] Mechanism developed at MIT and Massachusetts General Hospital shows promising results for improved ovarian cancer detection and removal.
	5.10 Traitements - Essais
Industry-backed project aims to become one-stop shop for clinical research data [Science] The idea for Vivli, from vivlíthiki, the Greek word for library, was articulated nearly 20 years ago in a dissertation written in the wake of the Human Genome Project.
	5.2 Pharma
Abemaciclib data highlight Eli Lilly’s case on CDK 4/6 [FierceBiotech] A new Phase I study covering a range of cancers and published in Cancer Discovery underscores some of the reasons why the FDA decided to hand out “breakthrough” status on abemaciclib. And it also highlights reasons why this drug still has potential to differentiate itself and vault ahead of its major league rivals.
Celator receives FDA breakthrough therapy designation for leukaemia drug [Pharmafile] Vyxeos performed well in late stage trials in older patients with previously untreated high-risk acute myeloid leukaemia (AML). The median overall survival for patients treated with the drug in the Phase III trial was 9.56 months, representing a 3.61 month improvement over other treatments.
	5.2.3 Pharma - économie
Genentech accused again of cheating health care providers [STAT] Yet another health care provider is accusing Genentech of fudging the amount of the Herceptin medicine that the company provides in each vial, causing the facility and many other hospitals to overpay for the pricey treatment.
Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation [The Street] Ziopharm's current enterprise value is almost $800 million, while Oncosec has a negative enterprise value of $2 million. But guess which company has better clinical data, to date? Oncosec.
	5.3 Traitements - FDA, EMA,...
Accessing key EMA information on human medicines [EMA] Providing an overview of the range of documents produced by EMA during the life span of a medicine, the guide covers early development, through initial evaluation, adoption of positive or negative opinions, post-authorisation changes and safety reviews.
	5.4 Traitements - Economie
Nice backs Novartis’ lung cancer drug [Pharmafile] Ceritinib has marketing authorisation in the UK as a treatment for anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC). Ceritinib is an ALK inhibitor. The company submission stated that the NHS list price is £4,923.45 for a 30-day supply.
	5.5.1.2 ASCO (général) - Académiques
Dana-Farber research presented at 2016 ASCO conference [Dana-Farber Cancer Institute] The 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) will include more than 70 research presentations by Dana-Farber Cancer Institute investigators.
	6. Lutte contre les cancers
More people caring for someone with cancer - survey [BBC News] The number of people caring for someone with cancer in the UK has risen to almost 1.5 million, new figures show. According to one leading charity, this is an increase of almost a third in the past five years.
NHS is 'not there' for individual cancer patients, top oncologist warns [The Telegraph] An NHS doctor for more than 40 years, he has written a book, The Street-Wise Patient’s Guide to Surviving Cancer, in which he warns that patients and their relatives need to become “exceptionally well informed” about their conditions to avoid being lost in the system.
Cancer Core Europe´s information hub: website now launched to update on the very latest from this inspired multi-center partnership [Vall d'Hebron Institute Oncology] The Cancer Core Europe´s pooling of exchange of expertise, research findings, common platforms and processes, will empower researchers and clinicians to rapidly exploit this trove of biological insights and clinical data for the benefit of patients.
	6.10 Politiques
The 21st Century Cures Act: Still alive, and still poised to endanger patients [Respectful Insolence] Although its advocates genuinely believe that its purpose is to bring cures faster to patients who need them, the 21st Century Cures Act will do no such thing, and tying changes in the FDA regulatory framework to increasing NIH funding is the ultimate cynical political ploy to gut the FDA and turn back the clock on drug development at least 50 years.
	6.11 Patients
My husband has ceased to exist – I still can’t understand how [The Guardian] He died in a hospital in Yale, New Haven, Connecticut, having bludgeoned his way on to a drug trial. He believed it might cure him. I suspect it may even have hastened his death.
	6.5 Médecines alternatives
Skin cancer patients face deadly risk using ‘black salve’ home remedy [Reuters] Black salve refers to products containing zinc chloride and sanguinarine, both corrosive ingredients that can severely damage skin, the study team writes in the Journal of the American Academy of Dermatology.
	6.6 Publications
Embrace preprints and set biomedical information free [STAT] There’s a moral aspect of preprints we should also keep in mind. Much of biomedical research is supported by taxpayer dollars. Our work is a public good, and we owe it to the people who pay for it to share it with the world as soon as possible.
Authors retract non-reproducible Cell paper [Retraction Watch] The authors revisited their experiments after another lab was unable to replicate their data, about proteins that may play a role in lung cancer.